300 IR
Trade Name
Orylmyte
Sublingual tablet
Request Type
New Registration
Drug Type
Biological
Approval Date
SFDA Approved Use
ORYLMYTE is indicated in adolescents (12-17 years) and adults for treatment of moderate to severe house dust mite-induced allergic rhinitis or rhinoconjunctivitis, diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE).